How big is XOMA Corp.?

As of Jun 18, XOMA Corp. has a market capitalization of 286.37 million, with net sales of 42.91 million and a net profit of -2.86 million over the last four quarters. As of Dec 24, shareholder's funds are 81.92 million and total assets are 226.96 million.

As of Jun 18, XOMA Corp. has a market capitalization of 286.37 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 42.91 million, while the sum of net profit for the same period is -2.86 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 81.92 million and total assets of 226.96 million.

What does XOMA Corp. do?

XOMA Corp. is a micro-cap biotechnology company focused on developing monoclonal antibody-based therapeutics. As of March 2025, it reported net sales of $16 million and a net profit of $2 million.

Overview:<BR>XOMA Corp. is a development-stage biotechnology company focused on the discovery and development of monoclonal antibody-based therapeutics, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 16 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 286.37 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.24 <BR>Return on Equity: -11.45% <BR>Price to Book: 3.38<BR><BR>Contact Details:<BR>Address: 2200 Powell St Ste 310, EMERYVILLE CA: 94608-1818 <BR>Tel: 1 510 2047239 <BR>Fax: 1 302 6555049 <BR>Website: https://www.xoma.com/

Should I buy, sell or hold XOMA Corp.?

Who are in the management team of XOMA Corp.?

As of March 2022, the management team of XOMA Corp. includes Mr. W. Denman Van Ness (Independent Chairman), Mr. James Neal (CEO), and several independent directors: Ms. Natasha Hernday, Ms. Barbara Kosacz, Mr. Joseph Limber, Mr. Matthew Perry, and Mr. Jack Wyszomierski. This team combines independent oversight with executive leadership for effective governance.

As of March 2022, the management team of XOMA Corp. includes the following members:<BR><BR>- Mr. W. Denman Van Ness, Independent Chairman of the Board<BR>- Mr. James Neal, Chief Executive Officer and Director<BR>- Ms. Natasha Hernday, Director<BR>- Ms. Barbara Kosacz, Independent Director<BR>- Mr. Joseph Limber, Independent Director<BR>- Mr. Matthew Perry, Independent Director<BR>- Mr. Jack Wyszomierski, Independent Director<BR><BR>This team comprises a mix of independent directors and key executives, reflecting a structure aimed at governance and strategic leadership.

Is XOMA Corp. overvalued or undervalued?

As of March 9, 2023, XOMA Corp.'s valuation has shifted from attractive to risky due to overvaluation indicated by high Price to Book and negative EV ratios, despite strong year-to-date and three-year returns compared to the S&P 500, suggesting caution for potential investors.

As of 9 March 2023, the valuation grade for XOMA Corp. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its Price to Book Value of 3.57, an EV to EBIT of -11.91, and an EV to EBITDA of -12.26, which suggest significant operational challenges. In comparison, peers such as Fusion Pharmaceuticals, Inc. report a P/E of -17.58 and Gossamer Bio, Inc. has a P/E of -4.38, highlighting that XOMA's valuation metrics are not competitive within its industry.<BR><BR>Despite the overvaluation, XOMA Corp. has shown strong returns, with a year-to-date return of 43.04% compared to the S&P 500's 12.22%, and a three-year return of 108.83% versus the S&P 500's 70.41%. However, the negative operational ratios and the recent downgrade in valuation grade suggest caution for potential investors.

Is XOMA Corp. technically bullish or bearish?

As of August 12, 2025, XOMA Corp. has a bullish technical trend supported by strong indicators, outperforming the S&P 500 with a year-to-date return of 43.04% compared to 12.22%.

As of 12 August 2025, the technical trend for XOMA Corp. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. Daily moving averages are bullish, and the On-Balance Volume (OBV) is bullish as well. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames.<BR><BR>In terms of performance, XOMA Corp. has outperformed the S&P 500 with a year-to-date return of 43.04% compared to the S&P's 12.22%, and a one-year return of 31.16% versus 17.14% for the index.